Product Description
Ahon Pharmaceutical Co., Ltd. is developing FCN-437C as a treatment for Advanced Breast Cancer and Female Breast Cancer. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT05438810)
Mechanisms of Action: CDK4 Inhibitor,CDK6 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ahon Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 11
Highest Development Phases
Phase 3: Breast Cancer|Male Breast Cancer
Phase 1: Hepatic Insufficiency|Liver Failure
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FCN-437c-III201 | P3 |
Recruiting |
Male Breast Cancer |
2024-09-20 |
|
| FCN-437c-CP-005 | P1 |
Completed |
Liver Failure|Hepatic Insufficiency |
2023-09-27 |
|
| FCN-437c-CP-004 | P1 |
Completed |
Breast Cancer |
2023-02-08 |
|
| CTR20220862 | P1 |
Completed |
Breast Cancer |
2022-06-30 |